ArticleClinical case reports2026
Pulse Steroid Therapy in a Patient With Refractory Rhabdomyolysis of Unknown Etiology: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pulse Steroid Therapy in a Patient With Refractory Rhabdomyolysis of Unknown Etiology: A Case Report.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhabdomyolysis is conventionally treated with aggressive fluid resuscitation and elimination of the inciting factor, whereas corticosteroids are typically limited to cases of immune-mediated myopathy. We describe an 18-year-old female who developed profound bilateral lower-limb swelling, bullae formation, and motor weakness following a viral prodrome. Laboratory evaluation revealed creatine phosphokinase exceeding 2000 IU/L (estimated by the laboratory staff to be ≈ 12,000 IU/L) and marked transaminitis with preserved renal function. Despite intensive hydration and low-dose corticosteroids, clinical and biochemical progression persisted, and extensive diagnostic workup remained negative. On hospital Day 9, intravenous methylprednisolone 500 mg daily was administered for three consecutive days. This was followed by rapid resolution of symptoms, normalization of muscle enzymes, and complete functional recovery by 3 months. The case suggests that early pulse corticosteroid therapy may avert irreversible muscle damage in selected patients with refractory rhabdomyolysis exhibiting inflammatory characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.